About this trial
This prospective study evaluates the safety of extending the interval of routine calendar-based follow-up visits from every 12 months to every 24 months in patients with type 1 diabetes who are in good glycemic control and suitable for remote monitoring. The primary outcome is the proportion of patients who maintain good glycemic control during the 24-month follow-up period.
Participants will attend two in-person visits at baseline (month 0) and at the end of follow-up (month 24), which include a comprehensive clinical examination, assessment of glucose control, and laboratory testing. One remote contact will occur at month 12 for prescription renewal and review of glucose data. Patients may contact their care unit as needed throughout the study. At the baseline and final visits, participants will complete a questionnaire assessing their perceived ability to manage self-care, the safety of the care plan, and their ability to contact their care provider when necessary.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Diagnosis of type 1 diabetes
Treatment with multiple daily injections or insulin pump therapy
Duration of diabetes ≥ 1 year
Disqualifiers
Age < 18 years
Duration of diabetes < 1 year
Pregnancy
Not using multiple daily injections or insulin pump therapy
Trial population
The study population includes adults (≥18 years) with type 1 diabetes in good glucose control and under the care of the Pirkanmaa Wellbeing Services County (Pirha).
Trial design
Cohort
Prospective
Treatments tested in this trial
Control visit interval
Other interventionStudy investigates whether it is safe to extend the interval of routine calendar-based follow-up visits from every 12 to every 24 months in patients with type 1 diabetes.
Treatment groups
Trial outcomes
Primary outcomes
Percentage of patients in good glycemic control
Percentage of patients with TIR \> 70%, GMI \< 53 mmol/mol, and HbA1c \< 53 mmol/mol
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: